Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EDIT Editas Medicine

Closed Memorial Day 05-22 16:00:00 EDT

2.76

+0.09

+3.37%

盘后2.76

+0.00-0.01%

19:20 EDT

High2.83	Low2.67	Vol1.02M
Open2.67	D1 Closing2.67	Amplitude5.99%
Mkt Cap269.43M	Tradable Cap247.25M	Total Shares97.62M
T/O2.81M	T/O Rate1.14%	Tradable Shares89.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EDIT","market":"US","secType":"STK","nameCN":"Editas Medicine","latestPrice":2.76,"timestamp":1779480000000,"preClose":2.67,"halted":0,"volume":1021334,"hourTrading":{"tag":"盘后","latestPrice":2.7596,"preClose":2.76,"latestTime":"19:20 EDT","volume":11045,"amount":30386.5362,"timestamp":1779492047697,"change":-0.0004,"changeRate":-0.000145,"amplitude":0.02163},"delay":0,"changeRate":0.033707865168539276,"floatShares":89583600,"shares":97618660,"eps":-1.178492,"marketStatus":"Closed Memorial Day","change":0.09,"latestTime":"05-22 16:00:00 EDT","open":2.67,"high":2.825,"low":2.665,"amount":2805491.5384596,"amplitude":0.059925,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.178492,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.67,"preHourTrading":{"tag":"盘前","latestPrice":2.6968,"preClose":2.67,"latestTime":"09:28 EDT","volume":192,"amount":509.45902079999996,"timestamp":1779456524683,"change":0.0268,"changeRate":0.010037,"amplitude":0.043745},"postHourTrading":{"tag":"盘后","latestPrice":2.7596,"preClose":2.76,"latestTime":"19:20 EDT","volume":11045,"amount":30386.5362,"timestamp":1779492047697,"change":-0.0004,"changeRate":-0.000145,"amplitude":0.02163},"volumeRatio":0.8678513624063525,"impliedVol":1.1509,"impliedVolPercentile":0.6693},"requestUrl":"/m/hq/s/EDIT","defaultTab":"news","newsList":[{"id":"2635740001","title":"Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635740001","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635740001?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:57","pubTimestamp":1778785068,"startTime":"0","endTime":"0","summary":"The analysts covering Editas Medicine, Inc. ( NASDAQ:EDIT ) delivered a dose of negativity to shareholders today, by...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/analyst-forecasts-just-became-more-bearish-on-editas-medicin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/analyst-forecasts-just-became-more-bearish-on-editas-medicin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQJ","IYW","QQQA","SQQQ","TQQQ","ONEQ","PSQ","QQQY","QYLG","QLD","FTEC","TECS","BK4139","QQQM",".IXIC","NDX","QQQE","QQQ","JEPQ","QDTE","TQQY","EDIT","BK4556","NQmain","NVIW.SI","MNQmain","QID","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635874635","title":"JonesTrading Keeps Their Buy Rating on Editas Medicine (EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635874635","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635874635?lang=en_us&edition=fundamental","pubTime":"2026-05-14 22:35","pubTimestamp":1778769333,"startTime":"0","endTime":"0","summary":"In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Editas Medicine, with a price target of $8.00. Peaker covers ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635716508","title":"Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635716508","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635716508?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:40","pubTimestamp":1778755255,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) said Thursday that preclinical data for its lead therapy, EDIT-401, reduced LDL cholesterol by an average of 90% across all dose groups in on-human primates, supporting its deve","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4556","DBB","BK4139","EDIT","LDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635771807","title":"Editas Medicine Reports New Preclinical Data Demonstrating Progress of Edit-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635771807?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:01","pubTimestamp":1778752860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA9HNTRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4139","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635713693","title":"Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2635713693","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635713693?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:01","pubTimestamp":1778752860,"startTime":"0","endTime":"0","summary":"New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 monthsCAMBRIDGE, Mass., May  14, 2026  (GLOBE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294685/0/en/Editas-Medicine-Reports-New-Preclinical-Data-Demonstrating-Progress-of-EDIT-401-as-Potential-Treatment-for-Hyperlipidemia-at-the-American-Society-of-Gene-and-Cell-Therapy-2026-Annu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","EDIT","AFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633120655","title":"Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD), Tempus AI, Inc. Class A (TEM) and Editas Medicine (EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633120655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633120655?lang=en_us&edition=fundamental","pubTime":"2026-05-08 02:00","pubTimestamp":1778176845,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Brookdale Senior Living (BKD), Tempus AI, Inc. Cla...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-brookdale-senior-living-bkd-tempus-ai-inc-class-a-tem-and-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-brookdale-senior-living-bkd-tempus-ai-inc-class-a-tem-and-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4613","BK4137","LU0128526141.USD","LABU","BK4551","BK4185","BK4581","BK4543","BK4528","LU1499592464.USD","BK4139","LU0029874061.USD","BK4587","BK4611","BK4585","TEMT","AI","LU2190626999.HKD","LU1861558580.USD","AIYY","BK4023","LU1861559042.SGD","EDIT","LU0842063009.USD","BK4121","BK4588","XBI","BKD","BK4556","TEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633922163","title":"Editas Medicine Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633922163","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633922163?lang=en_us&edition=fundamental","pubTime":"2026-05-06 05:01","pubTimestamp":1778014860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EDIT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 17:01 ET (21:01 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633968947","title":"Analyst Phil Nadeau Reiterates Buy on Editas Medicine, Citing Promising EDIT-401 Data, Strong Cash Runway, and Large Untapped HeFH Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2633968947","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633968947?lang=en_us&edition=fundamental","pubTime":"2026-05-06 00:56","pubTimestamp":1778000201,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Phil Nadeau has maintained their bullish stance on EDIT stock, giving a Buy rating today. Phil Nadeau has given his Buy rating due...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-phil-nadeau-reiterates-buy-on-editas-medicine-citing-promising-edit-401-data-strong-cash-runway-and-large-untapped-hefh-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-phil-nadeau-reiterates-buy-on-editas-medicine-citing-promising-edit-401-data-strong-cash-runway-and-large-untapped-hefh-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633891735","title":"Editas Medicine Q1 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2633891735","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633891735?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:32","pubTimestamp":1777980776,"startTime":"0","endTime":"0","summary":"Editas Medicine Q1 net loss narrowsOverviewU.S. gene editing firm's Q1 net loss narrowedCollaboration and other R&D revenue fell yr/yr due to end of prior collaborationOperating expenses declined, dri","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL1N41I0G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633912763","title":"Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633912763","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633912763?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:29","pubTimestamp":1777980582,"startTime":"0","endTime":"0","summary":"Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 39.53 percent increase over losses of $(0.43) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52277461/editas-medicine-q1-eps-0-26-beats-0-28-estimate-sales-2-831m-miss-4-065m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633791468","title":"BRIEF-Editas Medicine Q1 Net Income USD -24.982 Million Vs. IBES Estimate USD -26.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633791468","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633791468?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978849,"startTime":"0","endTime":"0","summary":"May 05  - Editas Medicine Q1 operating income USD -25.003 million.Q1 collaboration and other research and development revenue USD 2.8 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nPLXD09DB5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914853","title":"Editas Medicine Q1 Basic EPS USD -0.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914853?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nPLXD09DB5:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633368914","title":"Editas Medicine Q1 Collaboration and Other Research and Development Revenue USD 2.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633368914","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633368914?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978805,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nPLXD09DB5:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4139","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633774914","title":"Editas Medicine Announces First Quarter 2026 Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633774914","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633774914?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978800,"startTime":"0","endTime":"0","summary":"EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical data a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287494/0/en/Editas-Medicine-Announces-First-Quarter-2026-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4611","LU1861558580.USD","BK4556","BK4588","GLP","BK4590","LU1861559042.SGD","BK4139","CRSP","EDIT","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631539650","title":"Editas Medicine announces annual shareholder meeting via virtual webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2631539650","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631539650?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:54","pubTimestamp":1777409697,"startTime":"0","endTime":"0","summary":"Editas Medicine scheduled 2026 annual stockholder meeting to be held virtually via online webcast on June 17, 2026.Shareholders to vote on election of 2 Class I directors, each to serve until 2029 annual meeting.Advisory vote set on compensation for named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL541t2k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630310819","title":"Editas Medicine to present preclinical data for EDIT-401 hyperlipidemia therapy at conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2630310819","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630310819?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:33","pubTimestamp":1777322018,"startTime":"0","endTime":"0","summary":"Editas Medicine flagged new preclinical results for EDIT-401, its lead in vivo gene-editing candidate for hyperlipidemia.Data have not yet been presented; disclosures are scheduled for May 11-15 at ASGCT 2026.Separate oral presentations are set for May 13 at TIDES USA 2026 and May 25 at European Atherosclerosis Society Congress.Company positioned EDIT-401 as a potential durable treatment approach intended to lower LDL cholesterol in hyperlipidemia.Program update highlighted non-human primate evidence supporting meaningful LDL-C reduction, reinforcing a push toward a potentially transformative cardiovascular franchise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate thi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL9BQs9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628204821","title":"Editas publishes corporate presentation on in vivo gene editing, LDL-C lowering candidate EDIT-401","url":"https://stock-news.laohu8.com/highlight/detail?id=2628204821","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628204821?lang=en_us&edition=fundamental","pubTime":"2026-04-17 21:30","pubTimestamp":1776432651,"startTime":"0","endTime":"0","summary":"Editas highlighted lead in vivo gene-editing program EDIT-401 as a potential one-time treatment for hyperlipidemia, targeting LDLR upregulation via edits in non-coding regulatory regions.Preclinical data showed >90% mean LDL-C reduction in non-human primates.Development plan targets early human proof-of-concept data by end of 2026.Editas expects to complete enrollment in dose-finding portion in 2027, with topline results also slated for 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief on April 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL3pQ9jb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625966349","title":"Editas Medicine replaces Ernst & Young with PwC as auditor for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625966349","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625966349?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:29","pubTimestamp":1775593761,"startTime":"0","endTime":"0","summary":"Editas Medicine replaced Ernst & Young with PwC as independent auditor for fiscal year ending Dec. 31, 2026, effective April 1, 2026.Audit committee dismissed Ernst & Young following a formal review of proposals from other accounting firms.Ernst & Young audit reports for 2024 and 2025 carried no adverse opinion, disclaimer, or qualification.Editas reported no prior consultations with PwC on accounting, audit opinions, disagreements, or reportable events through April 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL54MNhx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625002604","title":"JonesTrading Sticks to Their Buy Rating for Editas Medicine (EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625002604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625002604?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:45","pubTimestamp":1775508317,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Editas Medicine, with a price target of $8.00. According to Tip...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622782450","title":"USPTO Ruling Impacts Editas Medicine CRISPR IP Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2622782450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622782450?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:52","pubTimestamp":1774615942,"startTime":"0","endTime":"0","summary":"Editas Medicine ( ($EDIT) ) has issued an update. Editas Medicine, Inc. is a biotechnology company focused on developing gene-editing therapies bas...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/uspto-ruling-impacts-editas-medicine-crispr-ip-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/uspto-ruling-impacts-editas-medicine-crispr-ip-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1487256676.USD","IP","LU2463526074.USD","BK4139","CRSP","BK4611","EDIT","BK4588","LU1481600234.SGD","LU1861558580.USD","LU1861559042.SGD","BK4136","LU1481599808.USD","BK4556","IE00B3T34201.USD","LU1169590202.USD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.editasmedicine.com","stockEarnings":[{"period":"1week","weight":0.0534},{"period":"1month","weight":-0.1712},{"period":"3month","weight":0.5419},{"period":"6month","weight":0.1405},{"period":"1year","weight":0.7037},{"period":"ytd","weight":0.3463}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.048743},{"month":2,"riseRate":0.5,"avgChangeRate":0.075357},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.053873},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.002841},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.006224},{"month":6,"riseRate":0.6,"avgChangeRate":0.089853},{"month":7,"riseRate":0.7,"avgChangeRate":0.035578},{"month":8,"riseRate":0.6,"avgChangeRate":0.036188},{"month":9,"riseRate":0.2,"avgChangeRate":-0.076361},{"month":10,"riseRate":0.4,"avgChangeRate":-0.058936},{"month":11,"riseRate":0.5,"avgChangeRate":0.071042},{"month":12,"riseRate":0.3,"avgChangeRate":0.023099}],"exchange":"NASDAQ","name":"Editas Medicine","nameEN":"Editas Medicine"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Editas Medicine(EDIT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Editas Medicine,EDIT,Editas Medicine股票,Editas Medicine股票老虎,Editas Medicine股票老虎国际,Editas Medicine行情,Editas Medicine股票行情,Editas Medicine股价,Editas Medicine股市,Editas Medicine股票价格,Editas Medicine股票交易,Editas Medicine股票购买,Editas Medicine股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Editas Medicine(EDIT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}